Megakaryocytic Progenitor Cells for Prophylaxis and Treatment of Thrombocytopenia

Summary

The purpose of this study is to evaluate the efficacy of ex vivo generated megakaryocytic progenitor cells (MPs) in prophylaxis and treatment of thrombocytopenia caused by chemotherapy in patients with acute leukemia (AL).

Conditions

• Hematological Diseases
• Thrombocytopenia

Interventions

BIOLOGICAL

MPs

MPs are generated from cord blood using a combination of cytokines.

DRUG

thrombopoietin (TPO) and interleukin-11

Platelet stimulating factors include thrombopoietin (TPO) and interleukin-11 and so on.

Sponsors & Collaborators

• Guangdong Provincial People's Hospital

  collaborator OTHER

• Third Affiliated Hospital, Sun Yat-Sen University

  collaborator OTHER

• Guangzhou General Hospital of Guangzhou Military Command

  collaborator OTHER

• Guangzhou First People's Hospital

  collaborator OTHER

• Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

  collaborator OTHER

• Southern Medical University, China

  collaborator OTHER

• Peking University People's Hospital

  collaborator OTHER

• Huazhong University of Science and Technology

  collaborator OTHER

• Sun Yat-sen University

  collaborator OTHER

• Academy Military Medical Science, China

  collaborator INDUSTRY

• Nanfang Hospital, Southern Medical University

  lead OTHER

Principal Investigators

• Qifa Liu, MD · Nanfang Hospital, Southern Medical University

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

14 Years

Max Age

65 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2014-09-30

Primary Completion

2016-09-30

Completion

2016-12-31

Countries

• China

Study Locations